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Figure: Inhibition of MMP-13 production. *Signiﬁcantly different
(p < 0.001).
The ability of APS to block MMP-13 production better than PRP is
likely due to its increased concentrations of anti-inﬂammatory cytokines.
Previous studies have shown APS has a greater fold increase of anti-
inﬂammatory cytokine concentrations from WB (see the table).
PRP APS
IL-1ra 3.2× 5.6×
sTNF-RI 2.4× 3.8×
sTNF-RII 2.6× 3.8×
Conclusions: APS has been shown to inhibit production of MMP-13,
a protein known to be responsible for cartilage degradation, more
effectively than WB or PRP. This is likely because APS contains higher
concentrations of anti-inﬂammatory cytokines. These results suggest that
APS may be more effective as a potential treatment for early OA, and
further studies are warranted.
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CUMULATIVE INCIDENCE OF ACL RECONSTRUCTION AFTER ACL
INJURY IN ADULTS: ROLE OF AGE, SEX AND RACE
J.E. Collins1,2, J.N. Katz1, S.D. Martin1, E. Losina1,2. 1Brigham and Women’s
Hosp., Boston, MA, USA; 2Boston Univ., Boston, MA, USA
Purpose: Anterior cruciate ligament (ACL) injuries are common,
potentially disabling and frequently prompt surgical reconstruction.
While the number of persons undergoing ACL reconstruction annually
is published, the proportion of ACL injured individuals who undergo
ACL reconstruction has not been examined rigorously. Our objectives
were to assess the 3-year cumulative incidence of ACL reconstruction
among those with ACL injury and to compare demographic and clinical
characteristics of those ACL injured patients that do and do not go on to
have ACL reconstruction.
Methods: We used a tertiary healthcare system Research Patient Data
Repository to identify patients diagnosed with an ACL injury (ICD-9
844.2) at Brigham and Women’s Hospital (BWH) between January 1,
2001 and January 1, 2008. We obtained follow-up data through 2011
to determine how many of those with ACL injury underwent ACL
reconstruction within three years of ACL injury diagnosis. We used
stratiﬁed analyses to examined incidence rates separately by sex, age,
and race. We built logistic regression models to estimate the likelihood
of ACL reconstruction among those with ACL injury adjusted for sex, age,
and race.
Results: There were 2,290 patients diagnosed with an ACL injury at
BWH between 2001 and 2008. The sample was 48% female and 52%
male and the average age was 47 (13.9). The 3-year cumulative of
incidence of ACL reconstruction after ACL injury was 28% (95% CI: (26.3%-
30.0%)). The majority of patients undergoing reconstruction did so within
6 months of injury diagnosis (87%) while 95% of patients underwent
reconstruction within 1 year. Men were more likely than women to have
ACL reconstruction following ACL injury (32% vs 24%). The likelihood of
reconstruction among ACL injured patients decreased with each decade
of age: 52% of 20–29 year olds had reconstruction compared to 10%
of 60–69 years olds. Whites were more likely to have reconstruction
than non-whites (29% vs 20%). Multivariable models showed signiﬁcant
associations between reconstruction and age, sex, and race. Men had 1.4
times the adjusted odds of reconstruction compared to women (95%CI:
(1.1–1.7)); Whites had 1.8 times the adjusted odds of reconstruction
compared to non-Whites (95% CI: (1.3–2.4)); and each decade of age
was associated with 0.6 times the adjusted odds of reconstruction
(95% CI: (0.51–0.62)). Stratiﬁed analyses (see Figure) show that among
patients less than 29, ACL injured females are more likely to undergo
reconstruction than ACL injured males, whereas among ACL injured
patients 30–60 males are more likely to undergo surgery.
Figure: Proportion with ACL reconstruction among those with an injury.
Conclusions: To our knowledge this is the ﬁrst study to report the 3-year
cumulative incidence rates of ACL reconstruction among those diagnosed
with an ACL injury. The odds of having an injury repaired are lower for
women and non-Whites, even after adjusting for age. The decrease in
ACL reconstruction in older ages could reﬂect differences in patients’
willingness to undergo surgery or in physicians’ assessment of clinical
need for surgery. These data could be used to estimate age/sex/race
speciﬁc prevalence of ACL injury in the US.
505
CHONDROCYTE GENETIC TYPING IN MASSIVE FRESH
OSTEOCHONDRAL ALLOGRAFT AT 18 MONTHS AFTER
TRANSPLANTATION: ARE THE CELLS STILL FROM THE DONOR?
S. Neri, F. Vannini, R. Buda, A. Rufﬁlli, M. Cavallo, G. Desando, B. Grigolo,
A. Facchini, S. Giannini. Istituto Ortopedico Rizzoli, Bologna, Italy
Purpose: Early post-traumatic arthritis poses a reconstructive challenge
for the young active patient. Fresh total shell osteochondral allograft
(FTSOA) represents a fascinating solution. Still, the survivorship of the
transplanted cartilage has not been fully investigated. Few reports exist
claiming the long term survivorship of the donor chondrocytes and the
inhability of the host cells to colonize the cartilage layer. Aim of this study
was to investigate the nature of the cells in the transplanted cartilage by
genetic typing at 18 months follow up after transplantation.
Methods: Eighteen patients, aged 42±12 years, received FTSOA, 3 of
total knee and 15 of total ankle. Cartilage biopsies were obtained during
revision (18±5 months) or second look surgeries (18±8 months) and
evaluated by histological and immunohistochemical analyses. Allograft
genetic typing compared to recipient and donor DNA was performed on
all the samples by microsatellite analysis. In addition, mRNA expression
of speciﬁc cartilage markers was evaluated on selected samples by Real-
Time RT-PCR.
Results: The 3 knee allografts were analyzed at revision for failure, while
12 out of 15 ankle allografts were analyzed at second look surgeries and
3 at revision for failure.
Histology and immunohistochemistry. All the three knee biopsies showed
the presence of cartilage tissue with many degenerative features
as conﬁrmed by immunohistochemical analyses of the presence of
some catabolic markers. For what is concerning ankle allografts,
cartilage specimens showed ﬁbrocartilagineous tissues with double
tidemark crossed by bundles of cells from subchondral bone;
immunohistochemical analyses revealed a strong positivity for type II
collagen at the extracellular level in the majority of the samples.
Genetic typing and mRNA expression. All the cartilage tissues from knee
allografts showed a mixed DNA proﬁle conﬁrming the presence of both
donor and recipient cells. On the contrary, almost all ankle allografts
typed (12 out of 15, including the three cases of failure) showed the
presence of recipient DNA into the allograft; 1 allograft showed a mixed
DNA proﬁle and 2 allografts matched with donor DNA proﬁle. Preliminary
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data on mRNA expression showed that allograft cartilage tissues express
cartilage speciﬁc markers.
Conclusions: The colonization of human viable knee and ankle allografts
by recipient cells was investigated by genetic typing and mRNA
expression. There is an evidence of persistence of donor cells particularly
in knee allografts. This event is rare in ankle allografts, where the
prevailing presence of host DNA suggests the ingrowth of recipient cells
into the allograft, presumably migrating from the subchondral bone, in
accordance with histological ﬁndings. The observed synthesis of cartilage
speciﬁc RNAs in some of the analysed samples argues for the acquisition
of a chondrocyte-like phenotype by some of these cells.
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HYMOVIS™, A HEXADECYLAMIDE HYALURONAN DERIVATIVE
(HYADD®4-G), INHIBITS GENE EXPRESSION CHANGES INDUCED BY
INTERLEUKIN-1b IN CHONDROCYTES AND SYNOVIAL FIBROBLASTS
DERIVED FROM OSTEOARTHRITIS PATIENTS
M.M. Smith1, A.K. Russell1, A. Schiavinato2, C.B. Little1. 1Kolling Inst.
(Univ. of Sydney), Royal North Shore Hosp., St Leonards, NSW, Australia;
2Fidia SpA, Abano Terme, Italy
Osteoarthritis (OA) involves pathological change in all joint tissues,
including cartilage degradation and synovitis. Synovial changes are
associated with pain, while cartilage loss is a major indication for
joint replacement. Cycloxygenase-2 (PTGS2) and inﬂammatory cytokines
(IL6, TNF) are implicated in pain and increasing degradative enzymes
and cartilage breakdown. A Cochrane study suggested positive clinical
beneﬁts of intra-articular hyaluronan (HA), despite its brief joint
residency time. An amide-derivative of HA (HYMOVIS™) with increased
joint retention was superior to native HA in improving gait, reducing
synovial hyperplasia and cartilage MMP13 expression in a sheep OA
model. To elucidate the mechanism of the improved in vivo effects with
the chemically modiﬁed HA, the effects of HYMOVIS™ on chondrocytes
and synoviocytes from OA patients were evaluated.
Chondrocytes (HAC, n = 6) and synoviocytes (HSF, n = 6) were isolated
from OA patients at the time of knee replacement. HYMOVIS™ or native
HA (0, 0.5, 1.0 or 1.5mg/mL) was added to primary HAC or early passage
HSF with interleukin-1b (IL1b, 2 ng/mL). Cultures were terminated
30 minutes later for Bioplex® quantitation of phosphoproteins (p-JNK,
p-NFúB, p-p38), or 24 hours later for RNA isolation and analysis of gene
expression by real time RT-PCR, and measurement of MMP13 activity in
the media. Only statistically signiﬁcant results are reported.
In both HAC and HSF IL1b increased expression of MMP1, MMP13, PTGS2,
IL6 (>100fold), all phosphoproteins (3–10fold) and MMP13 activity. Cell
speciﬁc effects were seen with IL1b increasing expression of ADAMTS4
in HAC; ADAMTS5 in HSF (~10fold); and causing a 2–3fold reduction of
mRNA for COL2A1 and ACAN in HAC and COL1A1 in HSF.
In both cell types, HYMOVIS™ added with IL1b decreased MMP13,
ADAMTS4, ADAMTS5, PTGS2, IL6 expression, normalized matrix protein
expression, but had no effect on phosphoproteins. Cell-type speciﬁc
effects included decreased MMP1 expression only in HSF, and reduced
MMP13 activity only in HAC. In HAC, HYMOVIS™ preincubation was
superior to simultaneous addition in reducing ADAMTS, MMP, PTGS2,
and IL6 expression, but it also inhibited expression of TIMP1 and TIMP3,
and abrogated the rescue of COL2A1 and ACAN expression. There was a
less dramatic effect of HYMOVIS™ preincubation on gene expression in
HSF compared with HAC.
These results demonstrated a signiﬁcant beneﬁcial effect of the
HA derivative, HYMOVIS™, on both synoviocyte and chondrocyte
metabolism in vitro. This suggests HYMOVIS™ may have broader
OA disease modifying actions and clinical beneﬁt by reducing the
negative effects of degradative enzymes and inﬂammatory cytokines
in comparison to native HA.
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EFFECTS OF SURGERY AND POST-OPERATIVE INTRA-ARTICULAR
CORTICOSTEROIDS ON SYNOVIAL FLUID COLLAGEN BIOMARKERS
IN AN EQUINE MODEL OF OSTEOARTHRITIS
J.M. Manfredi1, T.N. Trumble1, M. Boyce1, D. Groschen1, K.A. Merritt2,
M.P. Brown2. 1Univ. of Minnesota Coll. of Vet. Med., St Paul, MN, USA;
2Univ. of Florida Coll. of Vet. Med., Gainesville, FL, USA
Purpose: Little is known about collagen metabolism in the joint after
surgery and how anti-inﬂammatory drugs affect this metabolism. The
purpose of this study was to investigate the effects of arthroscopic
surgery and post-surgical intra-articular administration of triamcinolone
acetonide (TA) on collagen synovial ﬂuid biomarkers using an animal
model of osteoarthritis. We hypothesized that collagen synthesis and
degradation would increase in synovial ﬂuid after arthroscopic removal
of osteochondral fragments, and that there would be greater collagen
degradation in the TA treated group than in saline controls.
Methods: In 7 normal adult Quarter Horses an osteochondral fragment
was arthroscopically created on the dorsal medial aspect of the ﬁrst
phalanx in one randomly chosen metacarpophalangeal joint (MCPJ).
MCPJ synovial ﬂuid was collected on weeks 0 (fragment creation), 16
(fragment removal), 17, 18, and 20. After ﬂuid collection on week 17,
horses were divided into 2 treatment groups: (1) horses (n = 4) that
received 1mL TA (10mg) and (2) horses (n = 3) that received 1mL saline
injected into the MCPJ from which the fragment was removed. Effects of
surgery and TA treatment were evaluated in week 18 and 20 samples.
Injured MCPJ synovial ﬂuid CPII, C12C, C2C (IBEX Technologies), and CTXII
(IDS/Nordic) concentrations were evaluated using commercially available
ELISAs previously validated for equine use. Synovial ﬂuid biomarker
concentrations for all weeks were compared to each other using unpaired
t-tests. P< 0.05 was considered signiﬁcant.
Fig. 1. Mean±SD synovial ﬂuid biomarker concentrations for CP II (A),
C12C (B), C2C (C), and CTX II (D). Week 0 = osteochondral (OC) fragment
creation; week 16 = OC fragment removal (Sx); week 17 = 1 week
post OC fragment removal followed by intra-articular injection (arrow –
Tx Admin) of either triamcinolone acetonide (TA) or saline; week 18 =
2 weeks post OC fragment removal and 1 week post TA (black bar) or
saline (gray bar) injection; week 20 = 4 weeks post OC fragment removal
and 3 weeks post TA (black bar) or saline (gray bar) injection. Different
letters indicate signiﬁcance differences (P < 0.05).
Results: Sixteen weeks after creation of an osteochondral fragment,
concentrations of CPII, C2C, C12C, and CTX II all signiﬁcantly increased
